Oliveira Gabriel S, Costa Raquel P, Gomes Paula, Gomes Maria Salomé, Silva Tânia, Teixeira Cátia
ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, P-4050-313 Porto, Portugal.
I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, P-4200-135 Porto, Portugal.
Pharmaceuticals (Basel). 2021 Apr 2;14(4):323. doi: 10.3390/ph14040323.
Despite being considered a public health emergency for the last 25 years, tuberculosis (TB) is still one of the deadliest infectious diseases, responsible for over a million deaths every year. The length and toxicity of available treatments and the increasing emergence of multidrug-resistant strains of renders standard regimens increasingly inefficient and emphasizes the urgency to develop new approaches that are not only cost- and time-effective but also less toxic. Antimicrobial peptides (AMP) are small cationic and amphipathic molecules that play a vital role in the host immune system by acting as a first barrier against invading pathogens. The broad spectrum of properties that peptides possess make them one of the best possible alternatives for a new "post-antibiotic" era. In this context, research into AMP as potential anti-tubercular agents has been driven by the increasing danger revolving around the emergence of extremely-resistant strains, the innate resistance that mycobacteria possess and the low compliance of patients towards the toxic anti-TB treatments. In this review, we will focus on AMP from various sources, such as animal, non-animal and synthetic, with reported inhibitory activity towards .
尽管在过去25年里结核病一直被视为突发公共卫生事件,但它仍是最致命的传染病之一,每年导致超过100万人死亡。现有治疗方法的疗程和毒性,以及多重耐药菌株的不断出现,使得标准治疗方案的效率越来越低,并凸显了开发新方法的紧迫性,这些新方法不仅要具有成本效益和时间效益,而且毒性要更低。抗菌肽(AMP)是一类小的阳离子两亲性分子,通过作为抵御入侵病原体的第一道屏障,在宿主免疫系统中发挥至关重要的作用。肽所具有的广泛特性使其成为新“后抗生素”时代最有可能的替代物之一。在这种背景下,围绕极耐药菌株的出现、分枝杆菌固有的耐药性以及患者对毒性抗结核治疗的低依从性所带来的日益增加的危险,推动了将抗菌肽作为潜在抗结核药物的研究。在本综述中,我们将重点关注来自动物、非动物和合成等各种来源的抗菌肽,这些抗菌肽对……具有已报道的抑制活性。